Maridebart Cafraglutide (10mg)

What is Maridebart Cafraglutide (MariTide)?

Maridebart cafraglutide, also called AMG 133 or MariTide, is studied as a peptide-antibody conjugate. Its clinical construct combines GLP-1 activity with an antibody that blocks GIP receptors. The catalog lists a 10mg material whose exact construct needs confirmation.

Listed vial contents: 10mg. These are supplied quantities, not administration doses. Current pricing and availability are shown in the strength selector.

Which identity should I verify?

The published molecule includes an antibody domain and attached GLP-1 analogues. The catalog's approximate molecular weight does not establish equivalence to that complete conjugate. A peptide fragment cannot be assumed to reproduce the antibody's GIP-receptor activity; obtain matching construct and identity documentation.

What mechanisms are being studied?

GLP-1 agonism activates a receptor, while GIP antagonism blocks another receptor's signaling. This differs from tirzepatide, which activates both receptors. The antibody scaffold is central to interpreting the published conjugate's pharmacology.

What are the research questions?

• GLP-1 activation combined with GIP receptor blockade
• Antibody-conjugate versus peptide-fragment identity
• Construct-dependent receptor binding and pharmacology

What does the published work describe?

Véniant and colleagues' 2024 paper describes preclinical and phase 1 work on the antibody-peptide conjugate. It is evidence about that defined construct, not about an unspecified peptide sold under the same name. The page does not infer matching activity from the catalog label.

Experimental models in the cited papers

• Preclinical studies and phase 1 human research; defined AMG 133 antibody-peptide conjugate

What could future research explore?

Future research can distinguish the roles of the peptide and antibody domains. Meaningful comparisons require complete construct characterization before extrapolating conjugate findings to another research material.

These are research directions, not established applications of the product sold here.

What are the limits of this evidence?

An unresolved construct prevents direct attribution of the published conjugate's properties to this supplied material. Clinical findings apply to the tested formulation, trial population and study conditions. They do not establish the identity, safety or effectiveness of this laboratory vial. Research Use Only: this material is not a finished medicine.

Study references

1. Véniant MM, et al. A GIPR antagonist conjugated to GLP-1 analogues promotes weight loss with improved metabolic parameters in preclinical and phase 1 settings. Nat Metab. 2024. PMID 38316982

How should I check lot documentation?

Match the product, strength and lot to an original analysis document. Literature describes experimental findings; it does not verify the contents of this inventory. Generated sample reports illustrate the reporting flow and are not evidence of testing, purity or accreditation.